Real-world experience of secukinumab treatment for ankylosing spondylitis at the Royal National Hospital for Rheumatic Diseases, Bath

Williams, T, Wadeley, A, Bond, D, Cavill, C, Freeth, M and Sengupta, R (2020) 'Real-world experience of secukinumab treatment for ankylosing spondylitis at the Royal National Hospital for Rheumatic Diseases, Bath.' Clinical Rheumatology. ISSN 0770-3198

[img] Text
13128.pdf - Accepted Version
Restricted to Repository staff only until 27 January 2021.

Official URL: https://doi.org/10.1007/s10067-020-04944-5

Abstract

We reviewed our experience of treating ankylosing spondylitis patients with the IL-17 inhibitor secukinumab at the Royal National Hospital for Rheumatic Diseases, Bath. A total of 76 patients were included, of whom secukinumab was the first-line biologic drug used in 24, second line in 23, and third line in 29 patients, respectively. Only 5 patients discontinued the drug due to side effects before their first outpatient review, including 1 new case of inflammatory bowel disease. Significant improvements were seen in all disease outcome measures in patients receiving secukinumab as their first-line biologic agent, with a trend to improved mean BASDAI and BASFI even in patients receiving it as a second- or third-line biologic agent. This real-world analysis adds to the evidence recommending secukinumab as a largely safe and effective treatment for ankylosing spondylitis.

Item Type: Article
Note:

Categorised by the journal as a 'Brief Report'.

Keywords: ankylosing spondylitis, biologic disease-modifying drug, secukinumab
Divisions: School of Science
Date Deposited: 03 Mar 2020 14:15
Last Modified: 23 Mar 2020 16:03
Request a change to this item or report an issue Request a change to this item or report an issue
Update item (repository staff only) Update item (repository staff only)